Document Detail

High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus.
MedLine Citation:
PMID:  10501419     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the utility of systemic lupus erythematosus (SLE) initial clinical manifestations and the SLE Disease Activity Index (SLEDAI) for identifying patients who will have a remission. METHODS: We studied 100 SLE patients (85 females, 15 males) and identified all patients who had remission (defined as at least one continuous year during which lack of disease activity permitted withdrawal of all treatment to suppress general lupus activity of a particular clinical manifestation). Changes in laboratory parameters without clinical activity, thus not requiring treatment, did not invalidate remission. We did not include any patient who had never required treatment. We evaluated the SLEDAI values and the main SLE manifestations at the time of diagnosis of SLE, and also every 3 months during the first year of disease. RESULTS: Twenty-four of the 100 SLE patients achieved remission that occurred a mean of 64 months after the diagnosis. They remained in remission for a mean of 55 months. There were no statistical differences in SLEDAI values and the initial manifestations (including renal and cerebral) between patients who reached remission and those who did not. The patients who have a higher SLEDAI score take longer to achieve remission. CONCLUSION: SLE patients with severe initial clinical manifestations and higher SLEDAI values may achieve clinical remission.
F Formiga; I Moga; M Pac; F Mitjavila; A Rivera; R Pujol
Related Documents :
11454529 - The combination of thrombophilic genotypes is associated with definite antiphospholipid...
18528529 - Mcp-1 -2518 a/g single nucleotide polymorphism in slovak patients with systemic sclerosis.
7207769 - Central nervous system metastases in malignant melanoma.
15226559 - Lupus anticoagulant in immune thrombocytopenic purpura.
9696139 - Relationship between lupus nephritis activity and the serum level of soluble vcam-1.
8485559 - Calprotectin in patients with systemic lupus erythematosus: relation to clinical and la...
8500379 - Determination of inflammatory bowel disease activity by breath pentane analysis.
1741539 - Increased numbers of mast cells in bronchial mucosa after the late-phase asthmatic resp...
20616559 - Mri findings may predict early neurologic deterioration in acute minor stroke or transi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  38     ISSN:  1462-0324     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  1999 Aug 
Date Detail:
Created Date:  1999-10-20     Completed Date:  1999-10-20     Revised Date:  2007-09-06    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  724-7     Citation Subset:  AIM; IM    
Internal Medicine Service, Hospital de Bellvitge Princeps d'Espanya, L'Hospitalet de Llobregat, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Follow-Up Studies
Lupus Erythematosus, Systemic / diagnosis*,  therapy
Remission Induction
Severity of Illness Index

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein ...
Next Document:  Behçet's disease: evaluation of a new instrument to measure clinical activity.